Portola Pharmaceuticals Inc. | Key People and Executives
Hollings Chase Renton
Chairman
David C. Stump
Independent Director
Dennis M. Fenton
Independent Director
Laura A. Brege
Independent Director
John H. Johnson
Independent Director
Jeff W. Bird
Independent Director
Henry Ward Wolff
Independent Director
John T. Curnutte
Co-President, EVP-Research & Development
Mardi C. Dier
Co-President, Chief Financial Officer & EVP
John H. Lawrence
Chief Medical Officer & Senior Vice President
W. Richey Neuman
Vice President-Medical Affairs
Glenn Brame
Senior Vice President-Technical Operations
Tao Fu
Executive VP, Chief Commercial & Business Officer
Jeet Mahal
Vice President-Business Development
Anjali Pandey
Vice President-Medicinal Chemistry
Mark W. Gossett
Senior Vice President-Global Marketing
Cara Miller
Investor Relations Contact
Ernie Meyer
Chief Human Resources Officer & Executive VP
John B. Moriarty
Executive Vice President & General Counsel
Hollings Chase Renton
Chairman
Dennis M. Fenton
Independent Director
Laura A. Brege
Independent Director
John H. Johnson
Independent Director
Jeff W. Bird
Independent Director
Henry Ward Wolff
Independent Director
| Address |
270 East Grand Avenue
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.portola.com |
| Updated |
07/08/2019 |
| Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and hematologic disorders, and inflammation. Its FDA-approved medicines include Bevyxxa (betrixaban), the oral, once-daily Factor Xa inhibitor, and Andexxa coagulation factor Xa (recombinant), inactivated-zhzo, the antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company was founded by Charles J. |
